Senzime AB announced on May 27, 2026 that its TetraGraph neuromuscular monitoring system has received an additional FDA Class II 510(k) clearance. The new clearance, which follows a submission in April 2026, expands the system’s capabilities and reinforces its competitive advantages by including next‑generation features and future innovations. The enhanced TetraGraph platform is already cleared in the U.S. and CE‑marked in Europe, and is used to monitor neuromuscular blockade in anesthesia for improved patient safety and recovery.
Sources:
Senzime obtains FDA 510(k) clearance for enhanced TetraGraph ...
510(k) Premarket Notification - FDA
Senzime | Precision-based patient monitoring solutions
Senzime gets additional FDA class II 510(k) clearance for ...
Senzime secures the first sales in the US market
Next-generation TetraGraph quantitative train-of-four monitoring
Senzimes receives FDA 510k-clearance for a new disposable ...
Premarket Notification 510(k) - FDA
[PDF] August 17, 2022 Senzime AB Elisa Maldonado-Holmertz RA/QA ...